Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
HanAll BioPharma Co., Ltd. · CPP
Phase 4
Active, not recruiting
50
2026-07
Industry sponsor intelligence
HanAll BioPharma Co., Ltd.Clinical Pipeline.
Lead-sponsor view of HanAll BioPharma Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 50
Pipeline overview
Programs by phase and activity.
Velocity
HanAll BioPharma Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 30
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Leuprolide → | 1 | 0 | 0 | 0 | 1 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All HanAll BioPharma Co., Ltd. studies.
This page groups studies where HanAll BioPharma Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates